Document is current

Article History

Received: 22 October 2024

Accepted: 19 February 2025

First Online: 4 March 2025

Declarations

:

: Disclosures that might be interpreted as constituting possible conflict(s) of interest for the study. Javier Loricera had consultation fees/participation in company-sponsored speaker’s bureau from Roche, Galápagos, Novartis, UCB Pharma, MSD, Celgene, Astra Zeneca, and Grünenthal. He received support for attending meetings and/or travel from Janssen, Abbvie, Roche, Novartis, MSD, UCB Pharma, Celgene, Lilly, Pfizer, and Galápagos. Santos Castañeda has received research support from MSD and Pfizer and had consultation fees/participation in the company-sponsored speaker’s bureau from BMS, Eli-Lilly, MSD, Roche, and UCB. S. Castañeda is also assistant professor of the cátedra EPID-Future, funded by UAM-Roche, Universidad Autónoma de Madrid (UAM), Spain. Ricardo Blanco received grants/research support from AbbVie, MSD, and Roche. He also received consultation fees/participation in a company-sponsored speaker’s bureau from AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly, UCB, and MSD. The following authors did not declare financial disclosure: Carmen Secada-Gómez, Adrián Martín, Fernando López Gutiérrez, Lucía García-Alcalde, María Núñez-Sayar, Ander Ucelay-Aristi, Isabel Martínez Rodríguez.

: The study was approved by the Local Clinical Research Ethics Committee (ethical approval code: 2023.013) and was carried out following the protocol and the standard procedures that ensure compliance with Declaration of Helsinki and Good Clinical Practice standards. Animals were not involved in this research. According to the Clinical Research Ethics Committee in our center and according to the Spanish local legislation, this type of retrospective research did not require informed consent in our country.